Nuclear factor I-A (NFI-A) is a member of the NFI family of transcription factors, composed of four separate genes (Nfia, Nfib, Nfic, Nfix) with distinct functions depending on the cell type and target promoter context. 1, 2 Recent studies showed a novel and considerable role for NFI-A in the specification of hematopoietic lineages from CD34 þ human hematopoietic progenitor cells (HPCs). In particular, NFI-A was shown to promote the erythroid lineage at the expense of the granulocytic lineage, by direct repression of the G-CSF receptor (G-CSFR) gene, and to activate b-globin transcription in normal erythroblasts and remarkably in K562 chronic myeloid leukemia (CML) cells, which do not express endogenous b-globin. 2 Notably, NFI-A expression is shut off to allow terminal granulocytic or monocytic differentiation by the activity of microRNA-223 and microRNA-424, respectively, 3, 4 further indicating a common negative regulatory role for NFI-A in the myeloid lineage.
In line with these findings, we recently reported that exogenous NFI-A expression in K562 CML blast crisis cells resulted in a dramatic restoration of the normal erythroid program and increased differentiation responsiveness to the anti-metabolite cytosine arabinoside (Ara-C).
2 Notably, during Ara-C-induced differentiation of K562 wild-type cells, no NFI-A protein upregulation was observed compared to the physiological erythroid program of human HPCs, which is normally accompanied by increased NFI-A accumulation. 2 Altogether this evidence suggests a defective tumor suppressor-like function of NFI-A in K562 CML cells. In fact, a recent study performed using array-comparative genomic hybridization and DNA sequencing reported structural alterations of the NFI-A gene associated with different chronic malignant myeloid diseases. 5 In this study, to adequately dissect the molecular network downstream of NFI-A, we performed gene expression profiling of normal human uncommitted CD34
þ HPCs efficiently expressing exogenous NFI-A at high level. CD34
þ HPCs were purified from fresh cord blood obtained from healthy donors, pre-stimulated in serum-free medium supplemented with SCF 50 ng/ml, Flt3 ligand 50 ng/ml, IL-3 20 ng/ml and TPO 20 ng/ml overnight and transduced with a lentiviral vector encoding NFI-A or a control empty Vector as previously described. Forty-eight hours after transduction, GFP þ cells were sorted using FACSAria instrument (BD Biosciences, San Josè, CA, USA), subjected to total RNA extraction and hybridized on Agilent whole human genome oligo microarray (No. G4112F; Agilent Technologies, Palo Alto, CA, USA; detailed protocols are summarized in Supplementary Information).
To quantify the resulting amount of NFI-A in both the Vector and NFI-A samples, we performed a real-time PCR using primers specific for NFI-A (primers used are listed in Supplementary  Table S2 ). As shown in Figure 1a , the relative amount of NFI-A is greatly increased in the NFI-A-transduced compared to Vector-infected cells. Microarray results were then analyzed by using the GeneSpring GX 10 software (Agilent Technologies). Data transformation was applied to set all the negative raw values at 1.0, followed by a Quantile normalization. A filter on low gene expression was used to keep only the probes expressed in at least one sample (flagged as Marginal or Present). Expressed genes having a fold change of 41.5 between the Vector and NFI-A samples were selected. Interestingly, numerous genes were upregulated in the exogenous NFI-A-expressing sample, whereas relatively less genes were downregulated (for the complete raw and normalized data see Supplemental Table S1 ), suggesting that NFI-A per se behaves both as a transcriptional activator and repressor in undifferentiated CD34 þ cells. On careful analysis and classification of the data, we noted among the modulated genes a consistent number of erythroid genes. Many of these genes reflected an intermediate-to-mature erythroid developmental stage, and were in general accordance with recent genome-wide analyses performed on a variety of in vitro erythroid differentiation systems. [6] [7] [8] Out of this extensive number of potential target genes, a list of 27 genes corresponding to well-characterized erythroid-affiliated genes was used for cluster analysis of samples using the Euclidean distance as a measure of similarity ( Figure 1b) . As shown in Figure 1b , the NFI-A cells displayed considerable induction of erythroid cell membrane molecules, including CDH1, the Rh antigen family (RHAG; RHC/RHD), SLC4A1, AQP1, ADD3 and SPTB; molecules involved in the hemoglobin biosynthetic pathway, including ALAS2 and globin chains HBB, HBA and HBD; growth factors and growth factor receptors, including INHBA, EFBN2 and IGF2; signal transduction molecules, including JAK2, AKT2 and GAB1; transcription factors or DNA-binding proteins, including JUNB, HOXB8, KLF2, SSBP3 and TRIM10; finally, the intracellular transporter SELENBP1 as reported by Komor et al. 6 and Macaulay et al. 7 and reported in Supplementary References 1À27. Collectively, we can postulate that the gene expression profile analysis uncovered an extensive network of erythroid genes regulated after NFI-A expression, particularly erythroid membrane skeleton proteins and hemoglobin biosynthesis effectors. To validate the microarray data, we performed semiquantitative reverse transcription (RT)-PCR analysis of a few selected genes in CD34
þ HPCs transduced with Vector or NFI-A. As shown in Figure 1c , enforced expression of NFI-A parallels a vigorous accumulation of the selected mRNAs, confirming the gene expression profiling observations.
To extend the significance of the microarray data in a CML setting, we performed semiquantitative RT-PCR analysis of 10 modulated genes, selected for their biological relevance, in K562 CML blast crisis cells transduced with the control Vector or NFI-A with or without Ara-C treatment (Figure 2a Supplementary Table S2) , thus suggesting a defective pro-differentiating or tumor suppressor-like role of NFI-A in these cells. In fact, the kinetics of the tested mRNA accurately reflected the transcript profiles that emerged from the microarray performed in primary cells. The RT-PCR screening indicated several relevant NFI-Aregulated genes. However, gene expression alone cannot establish whether a transcription factor directly or indirectly binds to its target genes. To address this question, we focused on two genes that have been characterized for their essential function in erythroid cells: SLC4A1 and ALAS2. The SLC4A1 gene encodes the major anion exchanger of the red cell (chloride-bicarbonate) also called band 3, or anion exchanger 1 (AE1), (an integral component of the cytoskeletal network responsible for the unique functional properties of the erythrocyte membrane) whose alteration has been linked to the pathophysiology of dyserythropoietic conditions, (Supplementary References 5,28). ALAS2 represents the erythroid specific form of the ALAS enzyme, located in the mitochondria and expressed at high levels in red blood cells where it catalyzes the first step in the heme biosynthetic pathway. ALAS2 is mutated in X-linked sideroblastic anemia and knockout of ALAS2 leads to severe anemia with an increase in nucleated definitive red cells and accumulation of siderotic iron as reported in Supplementary References 29,30. To test whether NFI-A is actively recruited to the SLC4A1 and ALAS2 proximal promoters, we first scanned these regions in silico using UCSC genome browser (http:// genome.ucsc.edu/) combined with Chip-Mapper (http://bio. chip.org/mapper/mapper-main), Alibaba 2.1 (http://darwin.nmsu. edu/~molb470/fall2003/Projects/solorz/aliBaba_2_1.htm) and Mat-Inspector Professional (http://www.genomatix.de/products/ MatInspector/) software programs. Indeed, we found candidate NFI-A binding sites embedded in phylogenetically conserved regions approximately 750 and 75 bp upstream of the SLC4A1 (Supplementary Figure S1a) and ALAS2 (Supplementary Figure S1b) transcriptional start site, respectively. Chromatin immunoprecipitation was performed using an anti-NFI-A antibody and analyzed by real-time PCR in Vector-and NFI-A transduced K562 CML cells in the absence or presence of Ara-C as described 2 (chromatin immunoprecipitation primers are listed in Supplementary Table S2) . As a result, increasing NFI-A occupancy was observed on the proximal promoter regions of both SLC4A1 and ALAS2 genes only in exogenous NFI-Aexpressing cells in the presence of Ara-C, indicating a direct binding and transcriptional activation during erythroid differentiation (Figure 2b) .
In this study we established that NFI-A per se is able to induce an erythroid transcriptional program in both CD34
þ HPCs and leukemic K562 cells and acts directly at the proximal promoter regions of two fundamental erythroid genes, SLC4A1 and ALAS2. These results combined with our previous reports [2] [3] [4] show a critical role for NFI-A in the transcriptional activation of key erythroid molecules as well as its silencing as a prerequisite for myelopoiesis. In conclusion, we along with others 5 suggest that NFI-A alterations, such as aberrant genomic copy number or mutations, might entail a pathogenic relevance in hematological disorders, including leukemia, hemoglobinopathies, myeloproliferative and dyserythropoietic disorders.
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